Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease

被引:80
作者
Davis, Benjamin M. [1 ]
Pahlitzsch, Milena [1 ]
Guo, Li [1 ]
Balendra, Shiama [1 ]
Shah, Parth [1 ]
Ravindran, Nivedita [1 ]
Malaguarnera, Giulia [1 ]
Sisa, Claudia [1 ]
Shamsher, Ehtesham [1 ]
Hamze, Hisham [1 ]
Noor, Abdinasir [1 ]
Sornsute, Acom [2 ]
Somavarapu, Satyanarayana [2 ]
Cordeiro, M. Francesca [1 ,3 ]
机构
[1] UCL Inst Ophthalmol, London EC1V 9EL, England
[2] UCL Sch Pharm, London WC1N 1AX, England
[3] Imperial Coll London, Western Eye Hosp, ICORG, London NW1 5QH, England
来源
SCIENTIFIC REPORTS | 2018年 / 8卷
关键词
RETINAL GANGLION-CELLS; SOLID LIPID NANOPARTICLES; I CLINICAL-TRIAL; OPTIC-NERVE; AMYLOID-BETA; OXIDATIVE STRESS; HYPOXIA; PRESSURE; GLAUCOMA; DELIVERY;
D O I
10.1038/s41598-018-29393-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5dione) is a polyphenol extracted from turmeric that has long been advocated for the treatment of a variety of conditions including neurodegenerative and inflammatory disorders. Despite this promise, the clinical use of curcumin has been limited by the poor solubility and low bioavailability of this molecule. In this article, we describe a novel nanocarrier formulation comprising Pluronic-F127 stabilised D-a-Tocopherol polyethene glycol 1000 succinate nanoparticles, which were used to successfully solubilize high concentrations (4.3 mg/mL) of curcumin. Characterisation with x-ray diffraction and in vitro release assays localise curcumin to the nanocarrier interior, with each particle measuring < 20 nm diameter. Curcumin-loaded nanocarriers (CN) were found to significantly protect against cobalt chloride induced hypoxia and glutamate induced toxicity in vitro, with CN treatment significantly increasing R28 cell viability. Using established glaucoma-related in vivo models of ocular hypertension (OHT) and partial optic nerve transection (pONT), topical application of CN twice-daily for three weeks significantly reduced retinal ganglion cell loss compared to controls. Collectively, these results suggest that our novel topical CN formulation has potential as an effective neuroprotective therapy in glaucoma and other eye diseases with neuronal pathology.
引用
收藏
页数:13
相关论文
共 93 条
  • [1] Aihara M, 2014, MOL VIS, V20, P606
  • [2] Cobalt chloride, a chemical inducer of hypoxia-inducible factor-1α in U251 human glioblastoma cell line
    Al Okail, Majed S.
    [J]. JOURNAL OF SAUDI CHEMICAL SOCIETY, 2010, 14 (02) : 197 - 201
  • [3] PHARMACOLOGY OF CURCUMA-LONGA
    AMMON, HPT
    WAHL, MA
    [J]. PLANTA MEDICA, 1991, 57 (01) : 1 - 7
  • [4] Anand P., MOL PHARM, V4, P807
  • [5] Oxygen-dependent diseases in the retina: Role of hypoxia-inducible factors
    Arjamaa, Olli
    Nikinmaa, Mikko
    [J]. EXPERIMENTAL EYE RESEARCH, 2006, 83 (03) : 473 - 483
  • [6] Cantor L B, 1997, Expert Opin Investig Drugs, V6, P1063, DOI 10.1517/13543784.6.8.1063
  • [7] Possible role of excitotoxicity in the pathogenesis of glaucoma
    Casson, RJ
    [J]. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2006, 34 (01) : 54 - 63
  • [8] Cheng AL, 2001, ANTICANCER RES, V21, P2895
  • [9] Oxidative stress and mitochondrial dysfunction in glaucoma
    Chrysostomou, Vicki
    Rezania, Fatemeh
    Trounce, Ian A.
    Crowston, Jonathan G.
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2013, 13 (01) : 12 - 15
  • [10] Cordeiro M. F., 2017, BRAIN, V274, P61